6879968865 Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Zagazig University, Egypt.
Interactive Dermatology Research Group, Interactive Dermatology Foundation, Cairo, Egypt.
J Cutan Med Surg. 2021 Jul-Aug;25(4):377-383. doi: 10.1177/1203475421991130. Epub 2021 Feb 3.
Intralesional immunotherapy has been effectively used in the treatment of warts; however, comparative studies between different antigens are limited.
To evaluate the efficacy and safety of intralesional measles, mumps, and rubella (MMR) vaccine compared with intralesional antigen for the treatment of multiple common and plantar warts.
Sixty-eight adult patients with multiple common and plantar warts were randomly assigned into two groups, each containing 34 patients. The first group received intralesional MMR vaccine, while the second group received intralesional antigen. Each treatment was injected into the largest wart at 2-week intervals until complete clearance or for a maximum of 5 sessions.
The overall therapeutic response was higher in the antigen group (73.5%) compared with the MMR group (67.7%); however, the difference was not statistically significant. Complete clearance of common warts was higher in the antigen group, while that of plantar warts was higher in the MMR group. Adverse effects were transient and well tolerated in both groups. No recurrence was detected during the 6-month follow-up period.
Intralesional MMR and intralesional antigen showed comparable efficacy and safety in the treatment of common and plantar warts.
皮内免疫疗法已被有效地用于治疗疣；然而，不同抗原之间的比较研究有限。
评估麻疹、腮腺炎和风疹（MMR）疫苗与皮内抗原治疗多发性寻常疣和跖疣的疗效和安全性。
将 68 例多发性寻常疣和跖疣成年患者随机分为两组，每组 34 例。第一组接受皮内 MMR 疫苗治疗，第二组接受皮内抗原治疗。每 2 周注射一次最大的疣，直到完全清除或最多 5 次。
抗原组的总体治疗反应（73.5%）高于 MMR 组（67.7%）；然而，差异无统计学意义。抗原组寻常疣的完全清除率较高，而 MMR 组跖疣的完全清除率较高。两组的不良反应均为短暂且可耐受。在 6 个月的随访期间未发现复发。
皮内 MMR 和皮内抗原治疗寻常疣和跖疣的疗效和安全性相当。
